Advice
Following a full submission
Erlotinib (Tarceva®) is not recommended for use within NHS Scotland for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen.
The economic case has not been demonstrated.
The licence holder has indicated their decision to resubmit.
Download detailed advice76KB (PDF)
Medicine details
- Medicine name:
- Erlotinib (Tarceva®)
- SMC ID:
- 220/05
- Indication:
- Locally advanced or metastatic non small cell lung cancer after failure of at least one prior chemotherapy regimen
- Pharmaceutical company
- Roche
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Status
- Not recommended
- Date advice published
- 12 December 2005